الفهرس 
Systemic Lupus Erythematosus
Lupus nephritisOnly 14 pages are availabe for public view
 |  | from | 213 |  |  |
| | | from | 213 | | |
Abstract
Summary SLE is a chronic autoimmune disorder that can affect multiple organs including kidney. Suspicion of renal involvement when a patient with SLE develops proteinuria (>500 mg/day). HCQ has been used to treat mucocutaneous, musculoskeletal, serosal and constitutional manifestations of SLE. Also, it has been increased probability of remission in patients with LN, and even decreased probability of renal failure if used prior to the onset of LN. The aim of this work to evaluate the efficacy of HCQ in the treatment of proliferative LN classes III and IV in children and adolescents and to evaluate the side effects of HCQ. This non-randomized controlled study was carried out in Pediatric Nephrology Unit, Tanta University Hospitals upon 40 children aged ≤18 years old diagnosed according to SLICC criteria. They were classified into 2 groups: G(A): 20 cases on HCQ; the average daily dose is 5 mg/kg/day, G(B): 20 cases not receive HCQ. The study accepted from ethical committee of Faculty of Medicine, Tanta University with acceptance No.32490/7/18. Methods All Patients will be subjected to the following complete history taking; including age, sex, initial disease presentations, duration of disease, drugs history and family history. Full clinical examination: Including Measurements: Anthropometric measurement: weight, height and Body Mass Index (BMI). Vital measurement: Arterial blood pressure. Joints and lower limbs for edema. Mucocutaneous examination: malar rash, eczema,